Construction and Effectiveness Study of a Marketing Excellence System for Multinational Pharmaceutical Companies Under the Dual Drive of Compliance and Digitalization
DOI:
https://doi.org/10.71222/qfcq0380Keywords:
pharmaceutical companies, compliance management, digital marketing, business excellence, digital operationsAbstract
The marketing system in China is currently undergoing significant strengthening, and the rapid advancement of digitalization is being pushed forward at an unprecedented pace. This evolving landscape presents a critical challenge for multinational pharmaceutical companies, compelling them to urgently reconstruct and adapt their traditional marketing systems to maintain market relevance. Starting from the foundational positions of strict compliance management, advanced digital operations, and overall business excellence, this study constructs a comprehensive three-dimensional collaborative model integrating compliance governance, digital operations, and marketing capabilities. This innovative framework transitions organizational experience into standardized, intelligent workflows through institutionalized operation, data-driven decision-making, and the continuous capability improvement of internal institutions. From initial brand planning to comprehensive listing management, rigorous content review, dynamic customer operation, and continuous performance feedback, this proposed model systematically covers the entire operational process. The empirical evidence gathered in this study indicates that the implementation of this system substantially optimizes various critical aspects of pharmaceutical marketing. Specifically, it accelerates the speed of product listing, enhances cross-team collaboration, ensures the standardization of academic communication, and maximizes the efficiency of resource utilization. Ultimately, this dual-driven approach of compliance and digitalization plays a pivotal role in securing and sustaining the long-term competitiveness of multinational pharmaceutical enterprises operating within complex and highly regulated emerging markets.References
1. S. O. W. M. Y. A. Vedanabhatla and N. V. Gupta, "A review on audits and compliance management," Asian Journal of Pharmaceutical and Clinical Research, vol. 6, no. 2, pp. 43-45, 2013.
2. H. Chen, L. Qin, C. Jiang, M. Qin, Y. Sun, and J. Luo, "Characteristics, risk management and GMP standards of pharmaceutical companies in China," Frontiers in Public Health, vol. 11, p. 1103555, 2023.
3. J. Fisher, A. Aldea, and R. Bañares-Alcántara, "A compliance management system for the pharmaceutical industry," in Computer Aided Chemical Engineering, vol. 25, pp. 949-954, Elsevier, 2008.
4. D. E. Ekundayo, H. O. Sawyerr, O. A. Opasola, B. Y. Adiama, A. E. Aluko, A. R. Awoyemi, and A. D. Atimiwoaye, "Assessment of workers’ knowledge and compliance status of pharmaceutical industries environmental management plans (EMP)," Dutse Journal of Pure and Applied Sciences, vol. 11, no. 4d, pp. 202-224, 2025.
5. P. S. Kakade, S. N. Nagrale, V. Bharat, R. V. D. Babar, and P. S. Jagtap, "Regulatory Compliance in the Pharmaceutical Industry."
6. P. Ullagaddi, "Digital transformation in the pharmaceutical industry: Enhancing quality management systems and regulatory compliance," International Journal of Health Sciences, vol. 12, no. 1, pp. 31-43, 2024.
7. E. C. Chianumba, N. Ikhalea, A. Y. Mustapha, A. Y. Forkuo, and D. Osamika, "Enhancing corporate governance and pharmaceutical services through data analytics and regulatory compliance," International Journal of Advanced Multidisciplinary Research and Studies, vol. 4, no. 6, pp. 1613-1619, 2024.
8. I. Joseph, "Importance of compliance with regulations in the pharmaceutical industry," Available at SSRN 4679812, 2023.
9. S. S. Bawachkar, "Role Of Quality Assurance and Regulatory Compliance in Pharmaceutical Management," International Journal of Research & Technology, vol. 13, no. 4, pp. 109-125, 2025.
10. R. Jochem and K. Landgraf, "Quality management benchmarking: FDA compliance in pharmaceutical industry," International Journal of Health Care Quality Assurance, vol. 23, no. 8, pp. 690-698, 2010.
11. C. Jagun, "Strategies for Compliance with Government Regulation in a Pharmaceutical Company," Walden University, 2018.
12. F. Bruttin and D. Dean, "Managing the cost of compliance in pharmaceutical operations," IBM Business Consulting Services, 2004.
13. T. B. Nassè, I. Ansong, and F. Naatu, "Regulatory compliance and procurement practices: insights from pharmaceutical companies in Kumasi," International Journal of Pharmaceutical and Healthcare Marketing, vol. 20, no. 1, pp. 64-90, 2026.
14. U. Desale, "Critical Regulatory Controls within Pharmaceutical Corporation," Available at SSRN 4586967, 2023.
15. M. A. Amuta, M. Muonde, A. Y. Mustapha, and A. O. Mbata, "A risk management framework for navigating regulatory compliance in pharmaceutical sales and distribution operations," Decision Making, vol. 26, p. 27, 2020.
